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j.jtcvs.2012.08.074Reply to the Editor:
We thank Drs Young and Hopkins
for their kind remarks in favor of the
American Association for Thoracic
Surgery guidelines for lung cancer
screening with low-dose chest com-
puted tomographic scans. In creating
guidelines on the basis of a successful
research protocol, the Association
chose to expand the age of the screen-
ing population beyond the ages of the
participants in the National Lung
Screening Trial.1 The rationale behind
this decision included the age distribu-
tion of the disease in North America,
the fact that increasing age is an inde-
pendent risk factor for development of
cancer, and the improvement in308 The Journal of Thoracic and Cquality life years expected up to the
9th decade of life. Drs Young and
Hopkins offer additional justification
for this guideline, namely the age-
specific lung cancer mortality in the
United States increases exponentially
after the age of 50, with a peak at the
age of 80 years.
We envision a Web-based program
that would allow each citizen to cal-
culate his or her own absolute risk
of lung cancer, dissemination of eas-
ily updated educational materials,
and potential data collection for spe-
cific populations. It is our hope that
such risk assessment would in turn
lead to risk modification and smok-
ing cessation as integrated compo-
nents of patient care. Personal risk
calculators are currently available,
but they are not easily accessible to
the public. Such a Web-based tool
might convert a guideline or instruc-
tion into a conversation between
physician and patient, including the
opportunity to further patient interest
in smoking cessation.
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ASSUMPTIONS IN COST-
EFFECTIVENESS ANALYSIS
To the Editor:
We read with interest the Canadian
cost-effectiveness analysis by Doble
and colleagues1 comparing transcath-
eter aortic valve replacement (TAVR)
with standard management (SM) for
inoperable patients and with surgical
aortic valve replacement (SAVR) for
high-risk patients with severe,ardiovascular Surgery c January 2013operable aortic stenosis. Although
we found many aspects of this work
to be well done, we believe that the
published analysis contains a few im-
portant factual errors and a few as-
sumptions that have been
contradicted by recently published
follow-up data from the PARTNER
trial.
First, the Sapien valve (Edwards
Lifesciences LLC, Irvine, Calif)
price in Doble and colleagues’ analy-
sis1 ($37,606) is $13,606 greater
than the current Canadian price of
$24,000 (all figures are in Canadian
dollars). With no other changes to
the model of Doble and colleagues,1
correction of the Sapien valve price
would make TAVR slightly cost sav-
ing (by $2453) relative to SAVR
in high-risk surgical patients and
would reduce the incremental cost-
effectiveness ratio for TAVR relative
to SM from $36,458 to $20,497
per life year gained (or from $51,324
to $29,037 per quality-adjusted life
year gained). Second, Doble and col-
leagues1 estimated the costs of
SAVR in Ontario from provincial
data for patients aged 70 years and
older in Case Mix Group (CMG)
165, cardiac valve repair. SAVR pro-
cedures are not coded under this
CMG in Ontario, however, but rather
under CMG 162 (cardiac valve re-
placement), which has slightly higher
reimbursement. More importantly,
we believe that ‘‘average’’ reimburse-
ment values for SAVR in patients aged
70 years and older are likely to under-
estimate the true costs of SAVR
among patients like those in the
PARTNER trial, whose baseline char-
acteristics in the clinical trial placed
them in the highest 5% to 10% of
predicted operative risk.2
In projecting survival for inopera-
ble patients, Doble and colleagues1
used Canadian life table data for years
2 through 20 of their model for both
TAVR and SM patient cohorts. This
approach assumes that survivals be-
yond 1 year would be similar for the
two groups, in essence ignoring the
Letters to the Editorwell-documented excess long-term
mortality associated with uncorrected
severe aortic stenosis. In contrast,
recently published follow-up data
from the PARTNER trial3 showed
that among 1-year survivors, mortality
during year 2 of follow-up was signif-
icantly lower among TAVR patients
than among SM patients (18% vs
35%; hazard ratio, 0.58; P¼ .02). Do-
ble and colleagues’ approach1 is
therefore very likely to have underes-
timated the survival benefit that
TAVR provides for inoperable
patients.
Finally, in their model for high-risk
surgical candidates, Doble and col-
leagues1 assumed that the increased
risk of stroke with TAVR relative to
SAVR observed in the first year of
follow-up in the PARTNER trial
would continue at a constant rate
through the 20-year time horizon of
the model. Detailed analyses of neuro-
logic events in the PARTNER trial,4 as
well as recently published longer-term
follow-up data,5 suggest that after the
first 30 days of follow-up, stroke rates
for TAVR and SAVR were similar.
We believe that Doble and col-
leagues’ cost-effectiveness model1
should be updated in light of these im-
portant new data. If this were to be
done, the articles conclusions could
be significantly altered.
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COMPARING COLLOIDS IN
CARDIAC SURGERY?
To the Editor:
The publication by Navickis and
colleagues1 highlights a subject with
conflicting results in the literature,
the effect of hydroxyethyl starch
(HES) on bleeding after cardiac sur-
gery. Their study included 18 trials
with 970 patients reported between
1982 and 2008. The primary end point
was postoperative blood loss during
the first 24 postoperative hours, and
secondary end points were reoperation
for bleeding and blood product trans-
fusion within the same period. Na-
vickis and colleagues1 concluded that
HES 450/0.7 and 200/0.5 increased
postoperative blood loss, reoperation
rates and blood product transfusion
relative to albumin, with the statement
that despite the lack of sufficient direct
data for HES 130/0.4, its effects could
be assumed equivalent to those of HES
200/0.5 on the basis of head-to-head
comparisons.
In this valuable meta-analysis, we
think that there is yet another topic
to be discussed. The deleterious ef-
fects of HES solutions on bleeding
have been emphasized, but the possi-
ble positive effects of albumin onof Thoracic and Cardiovascular Surgecoagulation were not discussed. The
older meta-analysis by the same
group published in 2001 discussed
this topic in detail.2 In that article,
they stated that albumin, with its anti-
oxidant and free-radical scavenging
activity, may serve to avert bleeding
after cardiopulmonary bypass
(CPB).2 They also declared that albu-
min was shown to block erythrocyte
crenation caused by CPB and to pre-
serve functional and morphologic in-
tegrity of platelets, which are heavily
affected during CPB. They specu-
lated that the difference in bleeding
tendency could be attributable to the
deleterious effect of HES solutions
alone or in combination with protec-
tive effects of albumin. Lange and as-
sociates3 in their recent and very
detailed review on use of colloids in
cardiac surgery, defined the anticoag-
ulant action of albumin while sum-
marizing the characteristics of
colloids.3 Many controversial results
are being published regarding effects
of colloids on coagulation, so the ef-
fects of albumin on coagulation could
be detailed in this valuable meta-
analysis.
We believe that the discussion on
HES products and their effects on co-
agulation will continue. In particular,
since the retraction of the publications
of Boldt, who made substantial contri-
butions to the colloid-colloid and
colloid-crystalloid debates in favor
of HES, the subject has shifted to
a more complicated pattern, leading
readers to a more skeptical approach.
Physicians can benefit greatly from
meta-analyses such as that of Navickis
and colleagues.1 We as readers thank
the authors for sharing their knowl-
edge and the experience of their
detailed research.
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